Earnings Call · Q2 FY2022·2022-08-14

Q2 22EPS -68.42%·Rev n/aQ1 22EPS +6.25%·Rev n/aQ4 21EPS -10.53%·Rev n/aQ3 21EPS -2.70%·Rev n/a⚠ consensus missing

Processa Pharmaceuticals, Inc. PCSA

James Stanker — Investor Relations or Corporate Communications

David Young — Chief Executive Officer

+2.4%1d on move date+0.7% vs SPY3d−0.5%5d+3.3%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more PCSA calls or request research access.

More PCSA calls Browse calls Request research access